ArticleScientific reports2015
Identification of agents effective against multiple toxins and viruses by host-oriented cell targeting.
Article in Scientific reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- RanBP2 promotes ferroptosis resistance and compromises therapeutic response by stabilizing SLC7A1 through LRSAM1 SUMOylation and ubiquitination in lung adenocarcinoma.Cell death and differentiation · 2026Article
- The future of metronomic chemotherapy: experimental and computational approaches of drug repurposing.Pharmacological reports : PR · 2025Review
- C910 chemical compound inhibits the traffiking of several bacterial AB toxins with cross-protection against influenza virus.iScience · 2022Article
- Association between oral antimalarial medication administration and mortality among patients with Ebola virus disease: a multisite cohort study.BMC infectious diseases · 2022Article
- Article
- Antivirals against the Chikungunya Virus.Viruses · 2021Review
- Repurposing clinical drugs is a promising strategy to discover drugs against Zika virus infection.Frontiers of medicine · 2021Review
- Repurposing Quinoline and Artemisinin Antimalarials as Therapeutics for SARS-CoV-2: Rationale and Implications.ACS pharmacology & translational science · 2021Review
- Reno-protective effect of IL-34 inhibition on cisplatin-induced nephrotoxicity in mice.PloS one · 2021Article
- Identification of Bithionol, Dichlorophen, and Miconazole as Antibacterial Agents againstACS omega · 2020Article
- Repurposing Clinically Approved Drugs for the Treatment ofACS omega · 2020Article
- Exposure to Ebola Virus and Risk for Infection with Malaria Parasites, Rural Gabon.Emerging infectious diseases · 2020Article
- In Vivo Activity of Amodiaquine against Ebola Virus Infection.Scientific reports · 2019Article
- Drug repurposing: a promising tool to accelerate the drug discovery process.Drug discovery today · 2019Review
- DABMA: A Derivative of ABMA with Improved Broad-Spectrum Inhibitory Activity of Toxins and Viruses.ACS medicinal chemistry letters · 2019Article
- Effect of Mass Artesunate-Amodiaquine Distribution on Mortality of Patients With Ebola Virus Disease During West African Outbreak.Open forum infectious diseases · 2019Article
- Arbidol and Other Low-Molecular-Weight Drugs That Inhibit Lassa and Ebola Viruses.Journal of virology · 2019Article
- Role of a Small Molecule in the Modulation of Cell Death Signal Transduction Pathways.ACS infectious diseases · 2018Article
- Novel amodiaquine derivatives potently inhibit Ebola virus infection.Antiviral research · 2018Article
- ABMA, a small molecule that inhibits intracellular toxins and pathogens by interfering with late endosomal compartments.Scientific reports · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
A longstanding and still-increasing threat to the effective treatment of infectious diseases is resistance to antimicrobial countermeasures. Potentially, the targeting of host proteins and pathways essential for the detrimental effects of pathogens offers an approach that may discover broad-spectrum anti-pathogen countermeasures and circumvent the effects of pathogen mutations leading to resistance. Here we report implementation of a strategy for discovering broad-spectrum host-oriented therapies against multiple pathogenic agents by multiplex screening of drugs for protection against the detrimental effects of multiple pathogens, identification of host cell pathways inhibited by the drug, and screening for effects of the agent on other pathogens exploiting the same pathway. We show that a clinically used antimalarial drug, Amodiaquine, discovered by this strategy, protects host cells against infection by multiple toxins and viruses by inhibiting host cathepsin B. Our results reveal the practicality of discovering broadly acting anti-pathogen countermeasures that target host proteins exploited by pathogens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.